<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560780</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-007-11F</org_study_id>
    <nct_id>NCT01560780</nct_id>
  </id_info>
  <brief_title>Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis</brief_title>
  <official_title>Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized-controlled clinical trial that will randomize 120 patients undergoing
      clinically-indicated coronary artery bypass graft surgery to prasugrel at a dose of 10 mg
      daily or matching placebo for 12 months, starting at the time of hospital dismissal from
      surgery. The primary goal of the study is to determine whether prasugrel administration will
      prevent thrombus (clot) formation within a saphenous vein graft at 12 months, as examined by
      optical coherence tomography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortocoronary saphenous vein graft failure is common and is associated with high morbidity
      and mortality. Thrombus formation plays a critical role in early saphenous vein graft
      occlusion and may predispose to subsequent atherosclerosis formation. Optical coherence
      tomography is a novel, high-resolution, intravascular imaging technique that can reliably
      identify thrombus. Based on the findings of earlier VA Cooperative Studies, aspirin
      significantly reduces the incidence of early saphenous vein graft failure and is currently
      used in nearly all patients undergoing coronary bypass graft surgery. Administration of
      clopidogrel for improving early saphenous vein graft patency has provided conflicting results
      in small randomized studies. Prasugrel is a novel thienopyridine that provides more rapid,
      consistent, and intense platelet inhibition than clopidogrel. However, in patients who
      undergo coronary artery bypass graft surgery, it remains unknown whether prasugrel may
      decrease thrombus formation in saphenous vein grafts during the first postoperative year, and
      whether this will result in less saphenous vein graft wall thickening, less lipid deposition
      in the saphenous vein graft wall and fewer clinical events without increasing the risk for
      severe bleeding.

      Hypothesis: The investigators hypothesize that in patients undergoing clinically-indicated
      coronary artery bypass graft surgery, administration of prasugrel starting at dismissal from
      the index coronary bypass graft surgery hospitalization will result in lower prevalence of
      thrombus formation in a target SVG, as assessed by optical coherence tomography performed 12
      months post surgery compared to placebo, with similar incidence of major bleeding.

      This is a phase III, single-center, double-blind trial that will randomize 120 patients
      undergoing clinically-indicated coronary artery bypass graft surgery to prasugrel at a dose
      of 10 mg daily or matching placebo for 12 months, starting at the time of hospital dismissal
      from surgery. All patients will receive aspirin. Coronary angiography, optical coherence
      tomography, intravascular ultrasonography, and near-infrared spectroscopy of one target
      saphenous vein graft will be performed at 12 months to determine whether compared to placebo,
      administration of prasugrel will result in:

        1. Reduction of the prevalence of intragraft thrombus at 12-month follow-up optical
           coherence tomography imaging (primary efficacy endpoint)

        2. Similar incidence of severe bleeding using the Global Utilization of Streptokinase and
           t-PA for Occluded Coronary Arteries (GUSTO) criteria (primary safety endpoint)

        3. Reduction in the incidence of angiographic SVG failure (defined as 75% SVG diameter
           stenosis in at least one SVG); reduction in total and normalized total target saphenous
           vein graft atheroma volume, as assessed by intravascular ultrasonography; and reduction
           of saphenous vein graft lipid core burden index, as assessed at near-infrared
           intracoronary spectroscopy at 12-month follow-up cardiac catheterization (secondary
           endpoints)

        4. Reduction of major adverse cardiac events, defined as the composite of death, acute
           coronary syndrome, or coronary revascularization) during follow-up (secondary endpoints)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2013</start_date>
  <completion_date type="Actual">May 31, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Intragraft Thrombus at 12-month Follow-up Optical Coherence Tomography Imaging</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with intragraft thrombus seen at 12 month follow-up by optical coherence tomography in imaged saphenous vein graft</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Severe Bleeding Using the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) Criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with major bleeding defined by the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Angiographic Saphenous Vein Graft Failure</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with angiographic saphenous vein graft failure (defined as =75% SVG diameter stenosis in at least one saphenous vein graft)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Target Saphenous Vein Graft Atheroma Volume, as Assessed by Intravascular Ultrasonography</measure>
    <time_frame>12 months</time_frame>
    <description>Total target saphenous vein graft atheroma volume (mm3) as assessed by Intravascular ultrasound imaging in imaged saphenous vein grafts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saphenous Vein Graft Lipid Core Burden Index, as Assessed at Near-infrared Intracoronary Spectroscopy</measure>
    <time_frame>12 months</time_frame>
    <description>Lipid core burden as measured by Lipid Core Burden Index on near infrared intracoronary spectroscopy imaging of saphenous vein graft. Lipid Core Burden Index is defined as the fraction of pixels within the scanned region with a probability &gt;0.60 that a lipid core plaque is present (calculated by an algorithm developed to identify the NIRS signals associated with the molecular structure of lipids), multiplied by 1000 using EchoPlaque software (INDEC Medical Systems; Los Altos, CA) . Thus, the lipid core burden index (LCBI) is a quantitative summary metric of the probability of the presence of lipid within the scanned region, with a range of 0-1000, with higher indices indicating a higher proportion of pixels with a &gt;0.6 probability of lipid being present in the pullback of the catheter along the length of the entire vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events, Defined as the Composite of Death, Acute Coronary Syndrome, or Coronary Revascularization) During Follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with the composite outcome of death, acute coronary syndrome, or coronary revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized Total Target Saphenous Vein Graft Atheroma Volume, as Assessed by Intravascular Ultrasonography</measure>
    <time_frame>12 months</time_frame>
    <description>On IVUS images, atheroma volume was defined as the sum of the cross-sectional areas between the leading edges of the lumen and external elastic membrane. Total Target SVG atheroma volume was calculated as:
∑(EEM area - Lumen area).
Normalized atheroma volume represents the atheroma volume corrected for pullback length, and this parameter was calculated as:
∑(EEM area - Lumen area)/number of frames in pullback</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Coronary Artery Bypass</condition>
  <arm_group>
    <arm_group_label>Arm 1: Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prasugrel 10 mg by mouth daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo by mouth once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>one 10 mg tablet by mouth daily</description>
    <arm_group_label>Arm 1: Prasugrel</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo similar in appearance to prasugrel</description>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or greater

          -  Willing and able to give informed consent. The patients must be able to comply with
             study procedures and follow-up.

          -  Undergoing clinically-indicated coronary artery bypass graft surgery

        Exclusion Criteria:

          -  Known allergy to aspirin or prasugrel

          -  Need for concomitant cardiac procedure, such as valve repair or replacement

          -  Increased risk of bleeding, including need for warfarin or dabigatran administration

          -  Positive pregnancy test or breast-feeding

          -  Coexisting conditions that limit life expectancy to less than 12 months or that could
             affect a patient's compliance with the protocol

          -  Serum creatinine &gt; 2.5 mg/dL

          -  Severe peripheral arterial disease limiting vascular access

          -  Prior stroke or transient ischemic attack

          -  Weight &lt;60 kg or age &gt;75 years

          -  Multiple distal SVG anastomoses

          -  Postoperative complications prolonging hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuaib M. Abdullah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco VA Medical Center, San Francisco, CA</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Florida/South Georgia Veterans Health System, Gainesville, FL</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jesse Brown VA Medical Center Community-Based Outpatient Clinic Lake Side Divison, Chicago, IL</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 16, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <results_first_submitted>May 22, 2019</results_first_submitted>
  <results_first_submitted_qc>September 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2019</results_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Bypass</keyword>
  <keyword>thrombosis</keyword>
  <keyword>prasugrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT01560780/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Prasugrel</title>
          <description>prasugrel 10 mg by mouth daily
Prasugrel: one 10 mg tablet by mouth daily</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Placebo</title>
          <description>placebo by mouth once daily
Placebo: placebo similar in appearance to prasugrel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Clinical Follow-Up at 12 Months</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Study Drug for 12 Months</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Preference</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Prasugrel</title>
          <description>prasugrel 10 mg by mouth daily
Prasugrel: one 10 mg tablet by mouth daily</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Placebo</title>
          <description>placebo by mouth once daily
Placebo: placebo similar in appearance to prasugrel</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="7"/>
                    <measurement group_id="B2" value="64" spread="6"/>
                    <measurement group_id="B3" value="64" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Intragraft Thrombus at 12-month Follow-up Optical Coherence Tomography Imaging</title>
        <description>Number of patients with intragraft thrombus seen at 12 month follow-up by optical coherence tomography in imaged saphenous vein graft</description>
        <time_frame>12 months</time_frame>
        <population>In the prasugrel arm, 29 of the 42 patients underwent SVG angiography at 12 months (2 died, 11 did not want to undergo SVG angiography). Of these, 25 had interpretable OCT.
In the placebo arm, 30 of the 42 patients underwent SVG angiography at 12 months (1 died, 11 did not wish to undergo SVG angiography). Of these, 28 had interpretable OCT.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Prasugrel</title>
            <description>prasugrel 10 mg by mouth daily
Prasugrel: one 10 mg tablet by mouth daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>placebo by mouth once daily
Placebo: placebo similar in appearance to prasugrel</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Intragraft Thrombus at 12-month Follow-up Optical Coherence Tomography Imaging</title>
          <description>Number of patients with intragraft thrombus seen at 12 month follow-up by optical coherence tomography in imaged saphenous vein graft</description>
          <population>In the prasugrel arm, 29 of the 42 patients underwent SVG angiography at 12 months (2 died, 11 did not want to undergo SVG angiography). Of these, 25 had interpretable OCT.
In the placebo arm, 30 of the 42 patients underwent SVG angiography at 12 months (1 died, 11 did not wish to undergo SVG angiography). Of these, 28 had interpretable OCT.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Severe Bleeding Using the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) Criteria</title>
        <description>Number of patients with major bleeding defined by the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries criteria.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Prasugrel</title>
            <description>prasugrel 10 mg by mouth daily
Prasugrel: one 10 mg tablet by mouth daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>placebo by mouth once daily
Placebo: placebo similar in appearance to prasugrel</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Severe Bleeding Using the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) Criteria</title>
          <description>Number of patients with major bleeding defined by the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>safety end-point with p-value of &lt;0.05</non_inferiority_desc>
            <p_value>&gt;0.99</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Angiographic Saphenous Vein Graft Failure</title>
        <description>Number of patients with angiographic saphenous vein graft failure (defined as =75% SVG diameter stenosis in at least one saphenous vein graft)</description>
        <time_frame>12 months</time_frame>
        <population>In the prasugrel arm, 29 of the 42 patients underwent SVG angiography at 12 months (2 died, 11 did not want to undergo SVG angiography).
In the placebo arm, 30 of the 42 patients underwent SVG angiography at 12 months (1 died, 11 did not wish to undergo SVG angiography).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Prasugrel</title>
            <description>prasugrel 10 mg by mouth daily
Prasugrel: one 10 mg tablet by mouth daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>placebo by mouth once daily
Placebo: placebo similar in appearance to prasugrel</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Angiographic Saphenous Vein Graft Failure</title>
          <description>Number of patients with angiographic saphenous vein graft failure (defined as =75% SVG diameter stenosis in at least one saphenous vein graft)</description>
          <population>In the prasugrel arm, 29 of the 42 patients underwent SVG angiography at 12 months (2 died, 11 did not want to undergo SVG angiography).
In the placebo arm, 30 of the 42 patients underwent SVG angiography at 12 months (1 died, 11 did not wish to undergo SVG angiography).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Target Saphenous Vein Graft Atheroma Volume, as Assessed by Intravascular Ultrasonography</title>
        <description>Total target saphenous vein graft atheroma volume (mm3) as assessed by Intravascular ultrasound imaging in imaged saphenous vein grafts.</description>
        <time_frame>12 months</time_frame>
        <population>In the prasugrel arm, 29 of the 42 patients underwent SVG angiography at 12 months (2 died, 11 did not want to undergo SVG angiography). Of these, 25 had interpretable IVUS.
In the placebo arm, 30 of the 42 patients underwent SVG angiography at 12 months (1 died, 11 did not wish to undergo SVG angiography). Of these, 27 had interpretable IVUS.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Prasugrel</title>
            <description>prasugrel 10 mg by mouth daily
Prasugrel: one 10 mg tablet by mouth daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>placebo by mouth once daily
Placebo: placebo similar in appearance to prasugrel</description>
          </group>
        </group_list>
        <measure>
          <title>Total Target Saphenous Vein Graft Atheroma Volume, as Assessed by Intravascular Ultrasonography</title>
          <description>Total target saphenous vein graft atheroma volume (mm3) as assessed by Intravascular ultrasound imaging in imaged saphenous vein grafts.</description>
          <population>In the prasugrel arm, 29 of the 42 patients underwent SVG angiography at 12 months (2 died, 11 did not want to undergo SVG angiography). Of these, 25 had interpretable IVUS.
In the placebo arm, 30 of the 42 patients underwent SVG angiography at 12 months (1 died, 11 did not wish to undergo SVG angiography). Of these, 27 had interpretable IVUS.</population>
          <units>mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349" spread="189"/>
                    <measurement group_id="O2" value="358" spread="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saphenous Vein Graft Lipid Core Burden Index, as Assessed at Near-infrared Intracoronary Spectroscopy</title>
        <description>Lipid core burden as measured by Lipid Core Burden Index on near infrared intracoronary spectroscopy imaging of saphenous vein graft. Lipid Core Burden Index is defined as the fraction of pixels within the scanned region with a probability &gt;0.60 that a lipid core plaque is present (calculated by an algorithm developed to identify the NIRS signals associated with the molecular structure of lipids), multiplied by 1000 using EchoPlaque software (INDEC Medical Systems; Los Altos, CA) . Thus, the lipid core burden index (LCBI) is a quantitative summary metric of the probability of the presence of lipid within the scanned region, with a range of 0-1000, with higher indices indicating a higher proportion of pixels with a &gt;0.6 probability of lipid being present in the pullback of the catheter along the length of the entire vessel.</description>
        <time_frame>12 months</time_frame>
        <population>In the prasugrel arm, 29 of the 42 patients underwent SVG angiography at 12 months (2 died, 11 did not want to undergo SVG angiography). Of these, 12 had interpretable NIRS.
In the placebo arm, 30 of the 42 patients underwent SVG angiography at 12 months (1 died, 11 did not wish to undergo SVG angiography). Of these, 20 had interpretable NIRS.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Prasugrel</title>
            <description>prasugrel 10 mg by mouth daily
Prasugrel: one 10 mg tablet by mouth daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>placebo by mouth once daily
Placebo: placebo similar in appearance to prasugrel</description>
          </group>
        </group_list>
        <measure>
          <title>Saphenous Vein Graft Lipid Core Burden Index, as Assessed at Near-infrared Intracoronary Spectroscopy</title>
          <description>Lipid core burden as measured by Lipid Core Burden Index on near infrared intracoronary spectroscopy imaging of saphenous vein graft. Lipid Core Burden Index is defined as the fraction of pixels within the scanned region with a probability &gt;0.60 that a lipid core plaque is present (calculated by an algorithm developed to identify the NIRS signals associated with the molecular structure of lipids), multiplied by 1000 using EchoPlaque software (INDEC Medical Systems; Los Altos, CA) . Thus, the lipid core burden index (LCBI) is a quantitative summary metric of the probability of the presence of lipid within the scanned region, with a range of 0-1000, with higher indices indicating a higher proportion of pixels with a &gt;0.6 probability of lipid being present in the pullback of the catheter along the length of the entire vessel.</description>
          <population>In the prasugrel arm, 29 of the 42 patients underwent SVG angiography at 12 months (2 died, 11 did not want to undergo SVG angiography). Of these, 12 had interpretable NIRS.
In the placebo arm, 30 of the 42 patients underwent SVG angiography at 12 months (1 died, 11 did not wish to undergo SVG angiography). Of these, 20 had interpretable NIRS.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="9.3"/>
                    <measurement group_id="O2" value="7.4" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Events, Defined as the Composite of Death, Acute Coronary Syndrome, or Coronary Revascularization) During Follow-up</title>
        <description>Number of patients with the composite outcome of death, acute coronary syndrome, or coronary revascularization.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Prasugrel</title>
            <description>prasugrel 10 mg by mouth daily
Prasugrel: one 10 mg tablet by mouth daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>placebo by mouth once daily
Placebo: placebo similar in appearance to prasugrel</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Events, Defined as the Composite of Death, Acute Coronary Syndrome, or Coronary Revascularization) During Follow-up</title>
          <description>Number of patients with the composite outcome of death, acute coronary syndrome, or coronary revascularization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalized Total Target Saphenous Vein Graft Atheroma Volume, as Assessed by Intravascular Ultrasonography</title>
        <description>On IVUS images, atheroma volume was defined as the sum of the cross-sectional areas between the leading edges of the lumen and external elastic membrane. Total Target SVG atheroma volume was calculated as:
∑(EEM area - Lumen area).
Normalized atheroma volume represents the atheroma volume corrected for pullback length, and this parameter was calculated as:
∑(EEM area - Lumen area)/number of frames in pullback</description>
        <time_frame>12 months</time_frame>
        <population>In the prasugrel arm, 29 of the 42 patients underwent SVG angiography at 12 months (2 died, 11 did not want to undergo SVG angiography). Of these, 25 had interpretable IVUS.
In the placebo arm, 30 of the 42 patients underwent SVG angiography at 12 months (1 died, 11 did not wish to undergo SVG angiography). Of these, 27 had interpretable IVUS.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Prasugrel</title>
            <description>prasugrel 10 mg by mouth daily
Prasugrel: one 10 mg tablet by mouth daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>placebo by mouth once daily
Placebo: placebo similar in appearance to prasugrel</description>
          </group>
        </group_list>
        <measure>
          <title>Normalized Total Target Saphenous Vein Graft Atheroma Volume, as Assessed by Intravascular Ultrasonography</title>
          <description>On IVUS images, atheroma volume was defined as the sum of the cross-sectional areas between the leading edges of the lumen and external elastic membrane. Total Target SVG atheroma volume was calculated as:
∑(EEM area - Lumen area).
Normalized atheroma volume represents the atheroma volume corrected for pullback length, and this parameter was calculated as:
∑(EEM area - Lumen area)/number of frames in pullback</description>
          <population>In the prasugrel arm, 29 of the 42 patients underwent SVG angiography at 12 months (2 died, 11 did not want to undergo SVG angiography). Of these, 25 had interpretable IVUS.
In the placebo arm, 30 of the 42 patients underwent SVG angiography at 12 months (1 died, 11 did not wish to undergo SVG angiography). Of these, 27 had interpretable IVUS.</population>
          <units>mm3/frame</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.093" spread="0.045"/>
                    <measurement group_id="O2" value="0.079" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Prasugrel</title>
          <description>prasugrel 10 mg by mouth daily
Prasugrel: one 10 mg tablet by mouth daily</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Placebo</title>
          <description>placebo by mouth once daily
Placebo: placebo similar in appearance to prasugrel</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe GUSTO bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Percutaneous Coronary Intervention</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shuaib Abdullah</name_or_title>
      <organization>VA North Texas Healthcare System</organization>
      <phone>214-857-1458</phone>
      <email>shuaib.abdullah@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

